Citations

Showing 10 of 108094 citations.

Weight gain after breast cancer diagnosis: It's complicated…
Cathcart-Rake, Elizabeth , Sanft, Tara , Tevaarwerk, Amyé , Cathcart-Rake, Elizabeth J , Tevaarwerk, Amye J

Mayo Clinic

Cancer | July 4, 2022 | Volume: 128 | Issue: 17 | Pages: 3152-3154

10.1002/cncr.34343 | PMID 35781699 Get It

Sella and colleagues provide insight into the mechanisms potentially underlying weight changes for young survivors after a breast cancer diagnosis. However, policy and regulatory changes that target modifiable determinants of health with practical, sustainable interventions are needed to translate this information into meaningful action.
Epidemiology and Transmission Dynamics of COVID-19 in an Urban Pediatric US Population
Sebastian, Thresia , Carlson, Jesse J., Gaensbauer, James , Podewils, Laura Jean

Mayo Clinic

Public Health Reports® | July 4, 2022 | Volume: 137 | Issue: 5 | Pages: 1013-1022

10.1177/00333549221105232 | PMID 35786113 Get It

Objective: This analysis summarizes observational epidemiologic data and transmission dynamics of SARS-CoV-2 among people aged <18 years to better characterize the pediatric COVID-19 pandemic. Methods: We conducted a retrospective study of public health surveillance data among children in Denver, Colorado, who were reported to have COVID-19 from March 1, 2020, through September 30, 2021. We used descriptive statistics and bivariate rate ratios (RRs) to describe demographic and clinical characteristics, transmission dynamics, case trends, and ecological associations. Results: A total of 9815 children and adolescents who had COVID-19 were reported during the study period. Adolescents aged 14-17 years had the highest incidence rate (IR) per 1000 people (IR = 107.5; 3021 of 28 108). Hispanic/Latino children had a 1.6 times higher rate of infection than non-Hispanic White children (RR = 1.57; 95% CI, 1.50-1.65; P < .001). Few hospitalizations (n = 138, 1.4%) and deaths (n = 3, 0%) occurred. Most children were symptomatic (4487 of 5499, 81.6%). Within household clusters, a large proportion of pediatric cases (n = 6136) were a secondary case (n = 3959, 64.5%), followed by index case (n = 1170, 19.1%) and co–index case (n = 1007, 16.4%). Non-Hispanic White children had an increased risk of being an index or co–index case (RR = 1.14; 95% CI, 1.06-1.23; P < .001), while Hispanic/Latino children had an increased risk of being a secondary case (RR = 1.07; 95% CI, 1.03-1.11; P < .001). From 2020 to 2021, the association between pediatric case rates and neighborhoods with higher poverty and households with ≥3 people decreased. Conclusions: Older children and those identifying as Hispanic/Latino had a disproportionate incidence of disease. A sizable proportion of children were considered index cases or co–index cases. Pediatric prevention strategies, especially vaccinations, are vital for pandemic control.
Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease
Kim, Jin Wan , Dayah, Tariq, Javaid, Awad , Monlezun, Dominique , Balanescu, Dinu Valentin , Karimzad, Kaveh , Hakeem, Abdul , Boone, David L., Kim, Peter , Durand, Jean‐Bernard , Song, Juhee , Yang, Eric H. , Herrmann, Joerg , Marmagkiolis, Konstantinos , Toutouzas, Konstantinos , Johnson, Nils P. , Iliescu, Cezar , Monlezun, Dominique J , Iliescu, Cezar A , Yang, Eric , Balanescu, Dinu V , Donisan, Teodora , Boone, David L., Palaskas, Nicolas L , Lopez‐Mattei, Juan , Bălănescu, Șerban

Mayo Clinic

Medicina | July 3, 2022 | Volume: 58 | Issue: 7 | Pages: 884

10.3390/medicina58070884 | PMID 35888603 Get It

Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying significant coronary stenoses. We aimed to assess the specific management, safety and outcomes of FFR-guided percutaneous coronary intervention (PCI) in cancer patients with stable CAD. Materials and Methods: FFR was used to assess cancer patients that underwent coronary angiography for stable CAD between September 2008 and May 2016, and were found to have ≥50% stenosis by QCA. Patients with lesions with an FFR > 0.75 received medical therapy alone, while those with FFR ≤ 0.75 were revascularized. Procedure-related complications, all-cause mortality, nonfatal myocardial infarction, or urgent revascularizations were analyzed. Results: Fifty-seven patients with stable CAD underwent FFR on 57 lesions. Out of 31 patients with ≥70% stenosis as measured by QCA, 14 (45.1%) had an FFR ≥ 0.75 and lesions were reclassified as moderate and did not receive PCI nor DAPT. Out of 26 patients with <70% stenosis as measured by QCA, 6 (23%) had an FFR < 0.75 and were reclassified as severe and were treated with PCI and associated DAPT. No periprocedural complications, urgent revascularization, acute coronary syndromes, or cardiovascular deaths were noted. There was a 22.8% mortality at 1 year, all cancer related. Patients who received a stent by FFR assessment showed a significant association with decreased risk of all-cause death (HR: 0.37, 95% CI 0.15–0.90, p = 0.03). Conclusions: Further studies are needed to define the optimal therapeutic approach for cancer patients with CAD. Using an FFR cut-off point of 0.75 to guide PCI translates into fewer interventions and can facilitate cancer care. There was an overall reduction in mortality in patients that received a stent, suggesting increased resilience to cancer therapy and progression.
Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound
Schupack, Daniel , Johnson, Kimberly R. , Akambase, Joseph , Geno, Debra M., Lavey, Crystal, Lennon, Ryan J. , Snyder, Diana L. , Katzka, David A. , Alexander, Jeffrey A. , Schupack, D , Johnson, Kimberly , Akambase, Joseph A , Geno, Debra, Ravi, Karthik

Mayo Clinic

Diseases of the Esophagus | July 3, 2022 | Volume: 36 | Issue: 1 | Pages: No page available

10.1093/dote/doac040 | PMID 35780320 Get It

Summary Topical steroids are commonly used in treatment of eosinophilic esophagitis (EoE), but currently there is lack of data to clarify most effective regimen. We aimed to study the achievement of histologic remission using the same dose of budesonide in two different delivery formulations. Patients with established EoE treated with pharmacy compounded budesonide capsule or budesonide Rincinol gel (both 3 mg twice daily) were studied retrospectively. Those with pre-treatment and post-treatment histologic assessment were included with main endpoint being histologic remission. 103 patients (62 gel, 41 capsule) were included, with higher rate of histologic remission with gel (84 vs. 59%, P=0.004). A subset of patients in both groups had lack of steroid response (&lt;50% drop in eosinophils) (15% for gel, 32% for capsule). Formulation/delivery vehicle of steroid treatments to esophageal mucosa in EoE appears important for treatment efficacy, with budesonide gel having higher likelihood of histologic remission compared to budesonide capsules in our population. A truly steroid refractory group appears likely in our population. Larger, prospective studies may help clarify best regimen of topical steroids in EoE and may work to identify patients likely to benefit from alternative therapies.
Sotrovimab Lowers the Risk of COVID‐19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates
Sharif‐Askari, Fatemeh Saheb , Alsayed, Hawra Ali Hussain , Tleyjeh, Imad M. , Sharif‐Askari, Narjes Saheb , Hussain, Ali Al Sayed, Saddik, Basema , Hamid, Qutayba , Halwani, Rabih , Saheb Sharif-Askari, Fatemeh , Ali Hussain Alsayed, Hawra , Tleyjeh, Imad M , Saheb Sharif-Askari, Narjes

Mayo Clinic

Clinical Pharmacology & Therapeutics | July 3, 2022 | Volume: 112 | Issue: 6 | Pages: 1214-1223

10.1002/cpt.2700 | PMID 35780295 Get It

Sotrovimab, an anti‐severe acute respiratory syndrome‐coronavirus 2 monoclonal antibody is being utilized to prevent progression of coronavirus disease 2019 (COVID‐19). Therefore, to understand its benefits, we have conducted a retrospective analysis of all non‐hospitalized patients with symptomatic COVID‐19 who received a single infusion of sotrovimab and/or oral favipiravir at any Dubai COVID‐19 related healthcare center between July 1, 2021, and October 31, 2021. The main outcome was to evaluate the risk of hospitalization for patients with COVID‐19 or all‐cause death within 28 days of treatment initiation. In this analysis, which included 10,882 patients (1,135 in the sotrovimab group, 2,653 in the sotrovimab/favipiravir group, and 7,094 in the favipiravir group), sotrovimab or sotrovimab/favipiravir reduced the risk of hospitalization (13 patients (1.5%) in the sotrovimab group and 71 patients (2.9%) in the sotrovimab/favipiravir group vs. 251 patients (4%) in the favipiravir group; hazard ratio (HR) for sotrovimab: 0.16, 95% confidence interval (CI): 0.09–0.28, P < 0.001; and for sotrovimab/favipiravir, HR: 0.42, 95% CI: 0.32–0.56, P < 0.001), or death by day 28 from the start of treatment (no death in the sotrovimab group and 2 deaths in the the sotrovimab/favipiravir group vs. 10 deaths in the favipiravir group; odds ratio: 0.18, 95% CI: 0.04 to 0.81, P = 026). Safety was assessed in all the 3,788 patients in the sotrovimab and sotrovimab/favipiravir groups, and the reported adverse events were by 34 patients (<1%). In conclusion, sotrovimab was found to reduce the risk of progression of COVID‐19 when administrated early to non‐hospitalized patients with symptomatic COVID‐19. No safety concern was detected.
Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults
Nanba, Kazutaka , Baker, Jessica , Blinder, Amy, Bick, Nolan , Lim, Jung Soo , Wachtel, Heather , Cohen, Debbie L. , Williams, Tracy Ann , Reincke, Martín , Lyden, Melanie L. , Else, Tobias , Rainey, William E. , Wachtel, Heather , Williams, Tracy Ann , Reincke, Martin , Bancos, Irina , Else, Tobias , Rainey, William E , Nanba, Kazutaka , Liu, Chia‐Jen , Bancos, Irina , Young, William F. , Giordano, Thomas J. , Udager, Aaron M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 2, 2022 | Volume: 107 | Issue: 9 | Pages: 2473-2482

10.1210/clinem/dgac408 | PMID 35779252 Get It

Abstract Context Due to its rare incidence, molecular features of primary aldosteronism (PA) in young adults are largely unknown. Recently developed targeted mutational analysis identified aldosterone-driver somatic mutations in aldosterone-producing lesions, including aldosterone-producing adenomas (APAs), aldosterone-producing nodules (APNs), and aldosterone-producing micronodules, formerly known as aldosterone-producing cell clusters. Objective To investigate histologic and genetic characteristics of lateralized PA in young adults. Methods Formalin-fixed, paraffin-embedded adrenal tissue sections from 74 young patients with lateralized PA (&lt;35 years old) were used for this study. Immunohistochemistry (IHC) for aldosterone synthase (CYP11B2) was performed to define the histopathologic diagnosis. Somatic mutations in aldosterone-producing lesions were further determined by CYP11B2 IHC-guided DNA sequencing. Results Based on the CYP11B2 IHC results, histopathologic classification was made as follows: 48 APAs, 20 APNs, 2 multiple aldosterone-producing nodules (MAPN), 1 double APN, 1 APA with MAPN, and 2 nonfunctioning adenomas (NFAs). Of 45 APAs with successful sequencing, 43 (96%) had somatic mutations, with KCNJ5 mutations being the most common genetic cause of young-onset APA (35/45, 78%). Of 18 APNs with successful sequencing, all of them harbored somatic mutations, with CACNA1D mutations being the most frequent genetic alteration in young-onset APN (8/18, 44%). Multiple CYP11B2-expressing lesions in patients with MAPN showed several aldosterone-driver mutations. No somatic mutations were identified in NFAs. Conclusion APA is the most common histologic feature of lateralized PA in young adults. Somatic KCNJ5 mutations are common in APAs, whereas CACNA1D mutations are often seen in APNs in this young PA population.
Parallel functional annotation of cancer-associated missense mutations in histone methyltransferases
Cosgrove, Michael S. , Canning, Ashley J., Viggiano, Susan, Fernández-Zapico, Martín E.

Mayo Clinic

No container title available | July 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1746399/v1 Get It

Abstract Using exome sequencing for biomarker discovery and precision medicine requires connecting nucleotide-level variation with functional changes in encoded proteins. However, for functionally annotating the thousands of cancer-associated missense mutations, or variants of uncertain significance (VUS), purifying variant proteins for biochemical and functional analysis is cost-prohibitive and inefficient. We describe parallel functional annotation (PFA) of large numbers of VUS using small cultures and crude extracts in 96-well plates. Using members of a histone methyltransferase family, we demonstrate high-throughput structural and functional annotation of cancer-associated mutations. By combining functional annotation of paralogs, we discovered two phylogenetic and clustering parameters that improve the accuracy of sequence-based functional predictions to over 90%. Our results demonstrate the value of PFA for defining oncogenic/tumor suppressor functions of histone methyltransferases as well as enhancing the accuracy of sequence-based algorithms in predicting the effects of cancer-associated mutations.
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415
Khairnar, Rahul , DeMora, Lyudmila, Sandler, Howard M. , Lee, W. Robert , Villalonga-Olives, Ester , Mullins, C. Daniel , Palumbo, Francis B. , Bruner, Deborah Watkins , Shaya, Fadia T. , Bentzen, Søren M. , Shah, Amit B. , Malone, Shawn , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Albert, Michele, Pisansky, Thomas M. , Chen, Yuhchyau , Horwitz, Eric M. , DeNittis, Albert S., Feng, Felix Y. , Mishra, Mark V. , Bruner, Deborah , Horwitz, Eric M , Sandler, Howard M , Bentzen, Soren M , Mishra, Mark V , Dayes, Ian S , Seaward, Samantha A , Olives, Ester Villalonga , Currey, Adam D.

Mayo Clinic

JCO Clinical Cancer Informatics | July 1, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/cci.21.00188 | PMID 35776901 Get It

PURPOSE To compare the predictive ability of mapping algorithms derived using cross-sectional and longitudinal data. METHODS This methodological assessment used data from a randomized controlled noninferiority trial of patients with low-risk prostate cancer, conducted by NRG Oncology (ClinicalTrials.gov identifier: NCT00331773 ), which examined the efficacy of conventional schedule versus hypofractionated radiation therapy (three-dimensional conformal external beam radiation therapy/IMRT). Health-related quality-of-life data were collected using the Expanded Prostate Cancer Index Composite (EPIC), and health utilities were obtained using EuroQOL-5D-3L (EQ-5D) at baseline and 6, 12, 24, and 60 months postintervention. Mapping algorithms were estimated using ordinary least squares regression models through five-fold cross-validation in baseline cross-sectional data and combined longitudinal data from all assessment periods; random effects specifications were also estimated in longitudinal data. Predictive performance was compared using root mean square error. Longitudinal predictive ability of models obtained using baseline data was examined using mean absolute differences in the reported and predicted utilities. RESULTS A total of 267 (and 199) patients in the estimation sample had complete EQ-5D and EPIC domain (and subdomain) data at baseline and at all subsequent assessments. Ordinary least squares models using combined data showed better predictive ability (lowest root mean square error) in the validation phase for algorithms with EPIC domain/subdomain data alone, whereas models using baseline data outperformed other specifications in the validation phase when patient covariates were also modeled. The mean absolute differences were lower for models using EPIC subdomain data compared with EPIC domain data and generally decreased as the time of assessment increased. CONCLUSION Overall, mapping algorithms obtained using baseline cross-sectional data showed the best predictive performance. Furthermore, these models demonstrated satisfactory longitudinal predictive ability.
Racial and Ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center
Abdallah, Nadine , Purrington, Kristen S. , Tatineni, Sushma , Assad, Hadeel , Petrucelli, Nancie , Simon, Michael S. , Purrington, Kristen S

Mayo Clinic

No container title available | July 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1768808/v1 Get It

Abstract Purpose: The prevalence of pathogenic variants in BRCA1 and BRCA2 in populations other than Ashkenazi Jewish (AJ) is not well defined. We describe the racial and ethnic-specific prevalence of BRCA1/2 pathogenic variants and variants of uncertain significance (VUS) among individuals referred for genetic testing in a large urban comprehensive cancer center over a 20-year period. Methods: The population included 3,537 unrelated individuals who underwent genetic testing from January 1999 to October 2019 at the Karmanos Cancer Institute. We estimated the prevalence of pathogenic variants and VUS and evaluated associations with race and ethnicity for African American (AA), Arab, AJ and Hispanic individuals compared to Non-Hispanic Whites (NHW). We used multivariable models to adjust for other predictors of pathogenic variants. We also reported the most common pathogenic variants by racial and ethnic group. Results: The racial and ethnic breakdown of our population was: NHW (68.9%), AA (20.3%), AJ (2.5%), Arab (2.2%), Hispanic (1.0%), Asian Pacific Islander, Native American/Alaskan Native (4.7%), and <1% unknown. The overall prevalence of pathogenic variants in BRCA1/2 was 8.9% and the prevalence of VUS was 5.6%. Compared to NHW, there were no racial or ethnic differences in the rate of pathogenic variants. However, AA individuals were more likely to have VUS in BRCA1 (adjusted OR 2.43, 95% CI 1.38-4.28) and AJ more likely to have VUS in BRCA2 (adjusted OR 3.50, 95% CI 1.61-6.58).Conclusion: These results suggest the continued need for genetic testing and variant reclassification for individuals of all race and ethnic groups.
Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial
Packer, Douglas L. , Wilber, David J. , Dyrda, Katia , Nault, Isabelle , Killu, Ammar M. , Kanagasundram, Arvindh N. , Richardson, Travis D. , Stevenson, William G. , Curley, Michael , Investigators, for the SERF, Kapa, Suraj , Dyrda, Katia , Nault, Isabelle , Killu, Ammar M , Kanagasundram, Arvindh , Richardson, Travis , Stevenson, William , Verma, Atul , Curley, Michael , Kapa, Suraj , Verma, Atul , Investigators, for the SERF

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 1, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circep.121.010347 | PMID 35776711 Get It

Background: Ablation of ventricular tachycardia (VT) is limited by the inability to create penetrating lesions to reach intramyocardial origins. Intramural needle ablation using in-catheter, heated saline-enhanced radio frequency (SERF) energy uses convective heating to increase heat transfer and produce deeper, controllable lesions at intramural targets. This first-in-human trial was designed to evaluate the safety and efficacy of SERF needle ablation in patients with refractory VT. Methods: Thirty-two subjects from 6 centers underwent needle electrode ablation. Each had recurrent drug-refractory monomorphic VT after implantable cardioverter defibrillator implantation and prior standard ablation. During the SERF study procedure, one or more VTs were induced and mapped. The SERF needle catheter was used to create intramural lesions at targeted VT site(s). Acute procedural success was defined as noninducibility of the clinical VT after the procedure. Patients underwent follow-up at 30 days, and 3 and 6 months, with implantable cardioverter defibrillator interrogation at follow-up to determine VT recurrence. Results: These refractory VT patients (91% male, 66±10 years, ejection fraction 35±11%; 56% ischemic, and 44% nonischemic) had a median of 45 device therapies (shock/antitachycardia pacing) for VT in the 3 to 6 months pre-SERF ablation. The study catheter was used to deliver an average of 10±5 lesions per case, with an average of 430±295 seconds of radiofrequency time, 122±65 minute of catheter use time, and a procedural duration of 4.3±1.3 hours. Acute procedural success was 97% for eliminating the clinical VT. At average follow-up of 5 months (n=32), device therapies were reduced by 89%. Complications included 2 periprocedural deaths: an embolic mesenteric infarct and cardiogenic shock, 2 mild strokes, and a pericardial effusion treated with pericardiocentesis (n=1). Conclusions: Intramural heated saline needle ablation showed complete acute and satisfactory mid-term control of difficult VTs failing 1 to 5 prior ablations and drug therapy. Further study is warranted to define safety and longer-term efficacy. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03628534 and NCT02994446.